Yahoo Web Search

Search results

1. • 

     Older adults with aggressive blood cancer are responsive to treatment and show prolonged survival:...

     Medical Xpress· 1 day ago

     Standard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over...

2. • 

     Researchers discover new target for potential leukemia therapy

     Medical Xpress· 2 days ago

     The study provides both mechanistic and preclinical evidence supporting the rapid initiation of...

3. • 

     Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and...

     WTNH-TV New Haven· 3 days ago

     Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an...

4. • Deerfield Management and Deerfield Foundation Announce Second Annual AML Summit and Recipients of...

     The Pilot News· 4 days ago

     Deerfield Management and the Deerfield Foundation announced today they will honor the 2023-2024 recipients of the American Society of Hematology (ASH) Peter Steelman Scholar Award at the second ...

5. • PhALLCON Soars to New Heights—Faster, Stronger, but Better?

     Journal of the American Medical Association· 2 days ago

     In this issue of JAMA, Jabbour and colleagues1 report results from the interim analysis of the PhALLCON randomized trial with ponatinib vs imatinib, combined with reduced-intensity chemotherapy ...

6. • 

     GlycoMimetics reports Phase 3 trial of uproleselan falls short By Investing.com

     Investing.com· 4 days ago

     The study aimed to determine the efficacy of uproleselan in improving survival rates when used...

7. • Rigel Reports First Quarter 2024 Financial Results and Provides Business Update

     Lodi News-Sentinel· 3 days ago

     First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE® net product sales of $21.1 million and REZLIDHIA® net product sales of $4.9 millionExpanded Rigel's portfolio with acquisition of

8. • 

     Earnings call: Syndax Pharmaceuticals outlines robust Q1 2024 performance

     Investing.com· 2 days ago

     Syndax Pharmaceuticals , Inc. (NASDAQ: NASDAQ: SNDX ) has efficiently executed its corporate...

9. • Biomolecular atlas for bone marrow offers unprecedented window into blood production

     Medical Xpress· 4 days ago

     Researchers at Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania have revealed a powerful new bone marrow atlas that will offer ...

10. • Ligand Pharmaceuticals (NASDAQ:LGND) Posts Earnings Results, Beats Estimates By $3.01 EPS

      ETF DAILY NEWS· 3 days ago

      Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) released its quarterly earnings results on Tuesday. Ligand Pharmaceuticals had a return on equity of 11.98% and a net margin of 37.80%.